miglustat has been researched along with miglitol in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Aerts, JM; Bijl, N; Boot, RG; Copeland, D; Ghauharali, K; Groen, AK; Groener, JE; Liu, H; Meijer, AJ; O'Shea, TJ; Ottenhoff, R; Overkleeft, HS; Song, H; van den Berg, RJ; van der Marel, GA; van Eijk, M; Wennekes, T; Yew, N | 1 |
| Adachi, I; Hayashi, E; Hirono, S; Imahori, T; Kato, A; Koseki, J; Miyauchi, S; Nakagome, I; Nash, RJ; Natori, Y; Shimaoka, H; Takahata, H; Yoshimura, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cohen, S; Coste, S; Guffon-Fouilhoux, N; Guillaumont, M; Guitton, J; Manchon, M | 1 |
| Alonzi, DS; Becq, F; Best, D; Blériot, Y; Butters, TD; Fleet, GW; Jenkinson, SF; Kato, A; Kunimatsu, T; Martínez, RF; Mui, J; Nakagawa, S; Norez, C; Saville, AW; Weymouth-Wilson, AC; Wilson, FX | 1 |
| D'Alonzo, D; Dechecchi, MC; Esposito, A; Fenza, M; Gregorio, E; Guaragna, A; Lippi, G; Tamanini, A | 1 |
| Bennett, JJ; Murphy, PV | 1 |
2 review(s) available for miglustat and miglitol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis.
Topics: 1-Deoxynojirimycin; Anti-Inflammatory Agents; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Glycoside Hydrolases; Glycosyltransferases; Heterocyclic Compounds, 1-Ring; Humans; Imino Pyranoses; Inflammation; Molecular Structure; Mutation; Sequence Deletion; Tartrates | 2020 |
5 other study(ies) available for miglustat and miglitol
| Article | Year |
|---|---|
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
Topics: Absorption; Animals; Blood Glucose; Carbohydrate Metabolism; Glycated Hemoglobin; Glycosphingolipids; Imino Sugars; Mice; Mice, Obese; Obesity; Rats; Rats, Zucker; Structure-Activity Relationship; Viscera | 2010 |
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
Topics: Administration, Oral; Animals; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Imino Sugars; Inhibitory Concentration 50; Male; Mice; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2012 |
Rapid quantification of miglustat in human plasma and cerebrospinal fluid by liquid chromatography coupled with tandem mass spectrometry.
Topics: 1-Deoxynojirimycin; Calibration; Child; Chromatography, Liquid; Drug Stability; Enzyme Inhibitors; Humans; Least-Squares Analysis; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
C-branched iminosugars: α-glucosidase inhibition by enantiomers of isoDMDP, isoDGDP, and isoDAB-L-isoDMDP compared to miglitol and miglustat.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Angiogenesis Inhibitors; Biological Products; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Imino Sugars; Molecular Conformation; Stereoisomerism; Structure-Activity Relationship | 2013 |
Flow chemistry based catalytic hydrogenation for improving the synthesis of 1-deoxynojirimycin (DNJ) from an l-sorbose derived precursor.
Topics: 1-Deoxynojirimycin; Hydrogenation; Sorbose | 2023 |